Course Description
The COVID-19 pandemic had many potential impacts on people with mental health and substance use conditions, including direct consequences of infection, effects of infection control measures, and subsequent societal changes. Infection control impacted how mental health and substance use disorder care is delivered. To meet the needs, many strategies were developed, including telehealth and digital tools like apps and websites for therapy. This shift to telemedicine appears to be welcomed for use in some contexts and will likely outlast the pandemic. However, many fear it has potential negative impacts on rapport and therapeutic relationships. In addition, it does not meet the needs of individuals without the access and expertise necessary to use the technology. Determining when and where to continue using innovations developed during the pandemic is needed. This session will describe innovative and emerging opportunities utilized to expand access to mental health and substance use disorder care, outline strategies to remove barriers to care delivery by pharmacists, and highlight best practices and treatment standards that were applied during the pandemic.
- Gillespie C, Kleinberg F, Zogas A, Morreale A, Tran M, Moore T, Miller D, McCullough M. Perceptions of clinical pharmacy specialists’ contributions in mental health clinical teams. Ment Health Clin;12(1):15-22. https://doi.org/10.9740/mhc.2022.01.015
- Groppi J, Ourth H, Tran M, Morreale A, McFarland MS, Moore T, Jorgenson T, Torrise V. Increasing rural patient access using clinical pharmacy specialist providers: Successful practice integration within the Department of Veterans Affairs. AJHP 2021. https://doi.org/10.1093/ajhp/zxab011
- Moore T, Groppi J, Ourth H, Morreale A, Torrise V. Increasing Access to Care using Clinical Pharmacy Specialist Providers in Outpatient Mental Health: Successful Practice Integration within the Department of Veterans Affairs. JAPhA 2020;60:S107-S112.
Learning Objectives
- Assess how the COVID-19 pandemic impacted mental health/substance use disorder treatment standards and best practices.
- Evaluate innovations implemented during the COVID-19 pandemic to improve access to mental health/substance use disorder care during a time of crisis.
- Choose collaborative practice models that integrate pharmacist practitioners and enhance access to mental health/substance use disorder care.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Veldana Alliu, PharmD, BCPS
National Program Manager, Clinical Practice Integration and Model Advancement, Pharmacy Benefits Management, Clinical Pharmacy Practice Office
Veterans Health Administration
Tera Moore, PharmD, BCACP
National PBM Program Manager
Clinical Practice Integration and Model Advancement Pharmacy Benefits Management (PBM)
Aurora, CO
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 04/17/2023
ACPE Contact Hours: 1
ACPE Number: 0284-0000-23-005-H04-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2023 Program Committee and Recertification Editorial Board
 Elayne D. Ansara, PharmD, BCPP, BCPSProgram Committee Chair Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Bridget Bradley, PharmD, BCPP |
|
Austin R. Campbell, PharmD, BCPP |
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Jordan Cooler Haygood, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Marissa Cullen, PharmD, BCPP Clinical Pharmacist UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
 Beth DeJongh, PharmD, BCPP, BCPSRecertification Editorial Board Chair Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
|
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency VA Tennessee Valley Healthcare System Murfreesboro, TN External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Member of VA PBM Educational Advisory Committee which oversees Board Certification Study Groups |
Megan J. Ehret, PharmD, BCPP, MS |
|
Kimberly Ehrhard, PharmD Clinical Pharmacist, Psychiatry The University of Kansas Health System Kansas City , KS No Relevant Financial Relationships to Disclose |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Abigail Hampton, PharmD, BCPP Psychiatric Clinical Pharmacist - Ambulatory University of Kansas Health System Kansas City, KS No Relevant Financial Relationships to Disclose |
|
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Archana R. Jhawar, PharmD, BCPP Clinical Pharmacist Jesse Brown VAMC/ UIC College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Farah E. Khorassani, PharmD, BCPP Associate Clinical Professor St. John's University Queens, NY External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Consultant- Alkermes (Sept 2021) |
|
Dongmi Kim, PharmD, BCPP, BCPS Assistant Clinical Professor Fairleigh Dickinson University School of Pharmacy Florham Park, NJ No Relevant Financial Relationships to Disclose |
|
Jamie C. Kneebusch, PharmD, BCPP, BCPS Assistant Clinical Faculty UC San Diego, Skaggs School of Pharmacy La Jolla, CA No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Lauren E. Leiby, PharmD, BCPP Behavioral Health Patient Care Pharmacist Nationwide Childrens Hospital Columbus, OH No Relevant Financial Relationships to Disclose |
|
Amber R. Lemons, PharmD, BCPP Behavioral Health Pharmacist Denver Health Medical Center Denver, CO No Relevant Financial Relationships to Disclose |
|
Linda D. Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, CPNP Foundation Student Grant (Advisor), UGA College Pharmacy Ansel Fund |
|
Monica Mathys, PharmD, BCGP, BCPP Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
|
Lindsey N. Miller, PharmD, BCPP |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Assistant Director of Pharmacy;Residency Program Director RUHS Medical Center Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Jessica L. Mulhollan, PharmD, BCPP Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor Louis Stokes Cleveland VA Medical Center Cleveland, OH No Relevant Financial Relationships to Disclose |
|
Kristen Neumeister, PharmD, BCPP Clinical Pharmacist- Mental Health John Peter Smith Hospital Fort Worth, TX No Relevant Financial Relationships to Disclose |
|
Megan O'Connell, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland - Clifton T. Perkins Hospital jessup, MD No Relevant Financial Relationships to Disclose |
|
Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
|
Haley Pals, PharmD, BCPP Substance Use Disorder/Psychiatric Clinical Pharmacist Tomah VA Medical Center Tomah, WI No Relevant Financial Relationships to Disclose |
|
Brittany L. Parmentier, PharmD, BCPS, BCPP Clinical Assistant Professor University of Texas at Tyler Tyler, TX No Relevant Financial Relationships to Disclose |
|
Jake R. Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy/Indiana University Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
|
Heidi J. Wehring, PharmD, BCPP Adjunct Associate Professor of Psychiatry Maryland Psychiatric Research Center, University of Maryland School of Medicine Baltimore, MD No Relevant Financial Relationships to Disclose |
|
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.